WET AGE RELATED MACULAR DEGENERATION

This early-stage study tested the safety of SCAI-005 eye drops in 48 healthy adults. The goal was to see if the drug is safe and how it moves through the body. It is a first step toward a possible new treatment for wet age-related macular degeneration, a leading cause of vision l…

This early-phase study tested an eye drop called NT-101 in 20 people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The main goal was to check safety, and researchers also looked for signs that the drops might reduce fluid buildup and improve vis…

This study tested a new medicine called JL14002 against an existing drug (ranibizumab) for wet age-related macular degeneration, a condition that can cause rapid vision loss. The trial involved 443 adults aged 50 to 80 with active disease. The main goal was to see if JL14002 coul…

This study tested a new eye injection called EYP-1901 for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The goal was to see if EYP-1901 could control the disease as well as the standard treatment aflibercept, but with fewer injections. Th…

This study tested a new, low-cost eye-tracking system called CRYSTALSIGHT that uses artificial intelligence to monitor macular diseases like age-related macular degeneration and diabetic retinopathy. Twenty participants used the device at home to track eye movements, and research…